# Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma： A Randomized, Controlled Clinical Study

> **NCT03368131** · PHASE2 · UNKNOWN · sponsor: **Hebei Medical University** · enrollment: 48 (actual)

## Conditions studied

- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT03368131
- **Lead sponsor:** Hebei Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12-01
- **Primary completion:** 2019-12-30
- **Final completion:** 2020-12-31
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2020-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03368131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03368131, "Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma： A Randomized, Controlled Clinical Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03368131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*